What is the significance of WIPO Standard ST.26 in representing sequences in patent applications?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This is information only: it is not legal advice.
WIPO Standard ST.26 plays a crucial role in guiding the representation of nucleotide and amino acid sequences in patent applications. The MPEP 2412.05(e) frequently references this standard when describing how to handle various sequence scenarios in the Sequence Listing XML. For example:
- Paragraph 35 of ST.26 is cited for handling sequences constructed from non-contiguous segments.
- Paragraph 36 is referenced for sequences with known numbers of ‘n’ or ‘X’ residues.
- Paragraph 37 guides the representation of sequences with unknown gaps.
By adhering to WIPO Standard ST.26, patent applicants ensure that their sequence listings are consistent with international standards, facilitating examination and database compatibility. It’s important for applicants to familiarize themselves with these standards when preparing their sequence listings for patent applications.